To further validate our initial CRISPR screen, we performed a second, independent CRISPR screen using GL261 glioma model where we quantified the Chek2 KO clones in intracranial gliomas in WT and CD8 KO mice hosts over time. The gene discussed is CHEK2; the disease is central nervous system cancer.